

Fall 9-1-2016

Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

Myron S. Cohen

University of North Carolina at Chapel Hill

Ying Q. Chen

University of North Carolina at Chapel Hill

Marybeth McCauley

FHI 360, Washington, DC

Theresa Gamble

FHI 360, Durham, NC

Mina C. Hosseinipour

University of North Carolina at Chapel Hill

Tell us how you used this information in this [short survey](#).

Follow this and additional works at: https://digitalcommons.unmc.edu/com_internal_articles



Part of the [Primary Care Commons](#)

Recommended Citation

Cohen, Myron S.; Chen, Ying Q.; McCauley, Marybeth; Gamble, Theresa; Hosseinipour, Mina C.; Kumarasamy, Nagalingeswaran; Hakim, James G.; Kumwenda, Johnstone; Grinsztejn, Beatriz; Pilotto, Jose H.S.; Godbole, Sheela V.; Chariyalertsak, Suwat; Santos, Breno R.; Mayer, Kenneth H.; Hoffman, Irving F.; Eshleman, Susan H.; Piwowar-Manning, Estelle; Cottle, Leslie; Zhang, Xinyi C.; Makhema, Joseph; Mills, Lisa A.; Panchia, Ravindre; Faesen, Sharlaa; Eron, Joseph; Gallant, Joel; Havlir, Diane; Swindells, Susan; Elharrar, Vanessa; Burns, David; Taha, Taha E.; Nielsen-Saines, Karin; Celentano, David D.; Essex, Max; Hudelson, Sarah E.; Redd, Andrew D.; and Fleming, Thomas R., "Antiretroviral Therapy for the Prevention of HIV-1 Transmission." (2016). *Journal Articles: Internal Medicine*. 4.
https://digitalcommons.unmc.edu/com_internal_articles/4

This Article is brought to you for free and open access by the Internal Medicine at DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Internal Medicine by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Authors

Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, Nagalingeswaran Kumarasamy, James G. Hakim, Johnstone Kumwenda, Beatriz Grinsztejn, Jose H.S. Pilotto, Sheela V. Godbole, Suwat Chariyalertsak, Breno R. Santos, Kenneth H. Mayer, Irving F. Hoffman, Susan H. Eshleman, Estelle Piwowar-Manning, Leslie Cottle, Xinyi C. Zhang, Joseph Makhema, Lisa A. Mills, Ravindre Panchia, Sharlaa Faesen, Joseph Eron, Joel Gallant, Diane Havlir, Susan Swindells, Vanessa Elharrar, David Burns, Taha E. Taha, Karin Nielsen-Saines, David D. Celentano, Max Essex, Sarah E. Hudelson, Andrew D. Redd, and Thomas R. Fleming

ORIGINAL ARTICLE

Antiretroviral Therapy for the Prevention of HIV-1 Transmission

M.S. Cohen, Y.Q. Chen, M. McCauley, T. Gamble, M.C. Hosseinipour, N. Kumarasamy, J.G. Hakim, J. Kumwenda, B. Grinsztejn, J.H.S. Pilotto, S.V. Godbole, S. Chariyalertsak, B.R. Santos, K.H. Mayer, I.F. Hoffman, S.H. Eshleman, E. Piwowar-Manning, L. Cottle, X.C. Zhang, J. Makhema, L.A. Mills, R. Panchia, S. Faesen, J. Eron, J. Gallant, D. Havlir, S. Swindells, V. Elharrar, D. Burns, T.E. Taha, K. Nielsen-Saines, D.D. Celentano, M. Essex, S.E. Hudelson, A.D. Redd, and T.R. Fleming, for the HPTN 052 Study Team*

ABSTRACT

The authors' full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr. Cohen at the University of North Carolina Institute for Global Health and Infectious Diseases, Bioinformatics Bldg., 2nd Fl., 130 Mason Farm Rd., Suite 2115, CB #7030, Chapel Hill, NC 27599-7030, or at mcohen@med.unc.edu.

*A complete list of investigators in the HIV Prevention Trials Network (HPTN) 052 Study Team is provided in the Supplementary Appendix, available at NEJM.org.

This article was published on July 18, 2016, at NEJM.org.

N Engl J Med 2016;375:830-9.

DOI: 10.1056/NEJMoa1600693

Copyright © 2016 Massachusetts Medical Society.

BACKGROUND

An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples. ART was then offered to all patients with HIV-1 infection (index participants). The study included more than 5 years of follow-up to assess the durability of such therapy for the prevention of HIV-1 transmission.

METHODS

We randomly assigned 1763 index participants to receive either early or delayed ART. In the early-ART group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic millimeter). In the delayed-ART group, 877 participants started therapy after two consecutive CD4+ counts fell below 250 cells per cubic millimeter or if an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness) developed. The primary study end point was the diagnosis of genetically linked HIV-1 infection in the previously HIV-1–negative partner in an intention-to-treat analysis.

RESULTS

Index participants were followed for 10,031 person-years; partners were followed for 8509 person-years. Among partners, 78 HIV-1 infections were observed during the trial (annual incidence, 0.9%; 95% confidence interval [CI], 0.7 to 1.1). Viral-linkage status was determined for 72 (92%) of the partner infections. Of these infections, 46 were linked (3 in the early-ART group and 43 in the delayed-ART group; incidence, 0.5%; 95% CI, 0.4 to 0.7) and 26 were unlinked (14 in the early-ART group and 12 in the delayed-ART group; incidence, 0.3%; 95% CI, 0.2 to 0.4). Early ART was associated with a 93% lower risk of linked partner infection than was delayed ART (hazard ratio, 0.07; 95% CI, 0.02 to 0.22). No linked infections were observed when HIV-1 infection was stably suppressed by ART in the index participant.

CONCLUSIONS

The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners. (Funded by the National Institute of Allergy and Infectious Diseases; HPTN 052 ClinicalTrials.gov number, NCT00074581.)

ADVANCES IN THE TREATMENT AND CARE of patients with human immunodeficiency virus type 1 (HIV-1) infection have led to dramatic reductions in the morbidity and mortality associated with this disease.¹ However, despite intensive public health initiatives aimed at HIV-1 prevention, more than 2 million new HIV-1 infections were reported in 2014 worldwide.²

The global HIV-1 epidemic is primarily driven by sexual transmission.² Potent, durable HIV-1 prevention strategies are required to reduce the risk of viral transmission from infected persons to their sexual partners. Observational studies involving serodiscordant couples have suggested that antiretroviral therapy (ART) in persons with HIV-1 infection reduces the risk of sexual transmission of the virus.^{3,4} The multinational, randomized, controlled HIV Prevention Trials Network (HPTN) 052 trial was designed to determine the effect of ART on the transmission of HIV-1 from infected persons to their sexual partners.⁵⁻⁷

The HPTN 052 trial enrolled 1763 serodiscordant couples at 13 sites in nine countries. Index participants (i.e., those with HIV-1 infection) had CD4+ counts of 350 to 550 cells per cubic millimeter. Couples were randomly assigned to two study groups. In the early-ART group, index participants initiated ART at the time of enrollment. In the delayed-ART group, index participants initiated ART when two consecutive CD4+ counts fell below 250 cells per cubic millimeter or they had an illness indicative of the acquired immunodeficiency syndrome (i.e., an AIDS-defining illness).

In an interim analysis of study data that was performed in May 2011 after a median follow-up of 1.7 years, investigators found that early ART was associated with a 96% lower risk of index-to-partner, genetically linked HIV-1 infections than was delayed ART.⁵ The interim analysis also showed that early ART provided health benefits to the index participants.⁸ The data and safety monitoring board requested immediate release of those results. Accordingly, after May 2011, all index participants who were not already receiving ART were offered ART, regardless of the CD4+ count.⁶ The trial continued as prespecified through May 2015 to assess the durability of the effect of ART on HIV-1 transmission. This report presents the final results of the HPTN 052 trial.

METHODS

STUDY DESIGN

The HPTN 052 trial enrolled participants in Malawi, Zimbabwe, South Africa, Botswana, Kenya, Thailand, India, Brazil, and the United States, with pilot enrollment from April 2005 through May 2007 and full enrollment from June 2007 through May 2010.⁵ Detailed descriptions of the study and interim study results have been published previously.^{5,6,8} Data analysis was conducted in accordance with a prespecified analysis plan, as reported previously.^{5,8}

At enrollment, index participants reported no previous use of antiretroviral drugs, with the exception of short-term use for the prevention of mother-to-child transmission. Couples were randomly assigned to one of the two above-mentioned study groups. Prophylaxis with isoniazid or trimethoprim-sulfamethoxazole was provided to index participants according to local guidelines. Follow-up visits were conducted monthly for 3 months after enrollment and then quarterly.

CLINICAL AND LABORATORY EVALUATIONS

At the time of enrollment and at follow-up visits, index participants underwent clinical and laboratory evaluations and received condoms and counseling for risk reduction and medication adherence. Their partners who were free of HIV-1 infection were followed on the same visit schedule and were tested for HIV-1 at each study visit. Partner infections were confirmed at the HPTN Laboratory Center at Johns Hopkins University School of Medicine. After public release of the interim results in May 2011, all index participants were offered ART.

ASSESSMENT OF GENETIC LINKAGE

The genetic linkage of partner infections was assessed by means of phylogenetic analysis of HIV-1 polymerase (pol) region sequences, including sequences from index-partner pairs, sequences from unrelated index participants, and reference sequences. Probability of linkage was also assessed by means of Bayesian methods to compare genetic distances between sequences from index-partner pairs and unrelated participants. Selected cases were further analyzed by phylogenetic analysis of HIV-1 envelope (env) region sequences obtained with the use of next-



A Quick Take
is available at
NEJM.org

generation sequencing. Additional testing was performed to assess the timing of HIV-1 infection in selected cases. These methods have been described previously^{9,10} and are summarized in the Supplementary Appendix, which is available with the full text of this article at NEJM.org.

STUDY OVERSIGHT

The study was funded by the National Institute of Allergy and Infectious Diseases, which assumed all sponsor responsibilities through an investigational new-drug application with the Food and Drug Administration. The study protocol, available at NEJM.org, was approved by the institutional review board or ethics committee at each study site, as well as by other local regulatory bodies, as appropriate, and by the institutional review board at the U.S. Centers for Disease Control and Prevention (CDC) for the CDC-affiliated site in Kenya. All study participants provided written informed consent. The antiretroviral drugs that were used in the study were donated by Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, and Merck. The drug manufacturers were not involved in the design or management of the study or in the analysis or reporting of the data. The authors vouch for the completeness and accuracy of the data and the analysis and for the fidelity of this report to the protocol.

STATISTICAL ANALYSIS

A detailed description of the statistical considerations and the HPTN 052 statistical analysis plan have been published previously.⁷ The statistical analysis was performed on an intention-to-treat basis of the index participant's randomization assignment to assess the primary end point of incident partner infections during the study follow-up. If an HIV-1-negative partner was lost to follow-up before the primary end point was reached, the index partner remained in the study. In some cases, index participants found new partners who were willing to be enrolled. Such replacement partners were included in the statistical analysis as if they had been the original partners. Replacement partners were enrolled throughout the study, both before and after

the release of the interim study results. We used the Kaplan–Meier method to calculate cumulative event probabilities; person-year analyses were used to determine HIV-1 incidence rates before and after the public release of the interim study results. We used Cox regression models to estimate relative risk, as expressed by means of hazard ratios for the treatment effect of early ART versus delayed ART, with or without key baseline covariates, after adjustments, along with the 95% confidence intervals.

RESULTS

TRIAL PARTICIPANTS

The HPTN 052 trial enrolled 1763 serodiscordant couples (886 in the early-ART group and 877 in the delayed-ART group) (Fig. 1). The median follow-up time was 5.5 years (range, 0.0 to 9.9) for the early-ART group and 5.5 years (range, 0.1 to 9.9) for the delayed-ART group. The interim study results were released to the public on May 12, 2011. At that time, 1702 (97%) of the index participants remained in the study, along with 1563 (89%) of the partners, including 3 partners who were retained after the index participant discontinued involvement in the study. Rates of retention were similar in the two study groups (Fig. S2 in the Supplementary Appendix). By the end of the study (May 2015), 1536 (87%) of the index participants remained in the study, with 10,031 person-years of follow-up; 1165 (66%) of the couples remained in the study, with similar distribution in the two study groups (Fig. S2 in the Supplementary Appendix). Partners were followed for 8509 person-years. Rates of annual visit attendance among the partners were similar in the two study groups; the reasons for early discontinuations among the partners are shown in Figure 1.

Among male partners, there was no significant between-group difference in the rate of circumcision between the early-ART group and the late-ART group during the course of the study (22.3% and 18.3%, respectively; $P=0.13$). The rates of sexually transmitted infections that were detected among the index participants were also similar in the two study groups (Table S1 in the Supplementary Appendix).




Figure 1. Study Randomization and Outcomes.

Shown are data on the randomization of couples, enrollment of partners, partner visit attendance, and reasons for early discontinuation of partners in the study. Thirty additional partners (17 in the early-ART group and 13 in the delayed-ART group) were enrolled throughout the course of the study to replace partners who discontinued their participation in the study before reaching a primary study end point. The four partners who were found to have HIV-1 infection at study enrollment were excluded from the analysis. Visit attendance is shown for annual visits only; actual study visits occurred at least quarterly. The data for annual visit attendance are presented as the number of partners (nonindex participants) who were retained per the number who were expected at each year-end visit. The number retained refers to the number of partners who completed visits or reached a study end point (i.e., death of the index participant or the diagnosis of HIV-1 infection in the partner). The expected number refers to the number of partners who did not discontinue participation in the study because of death or the termination of the relationship with the index participant before the end of the allowable visit period.

Table 1. Incidence of All Partner Infections and Linked Partner Infections, before and after the Interim Analysis.*

Type of Infection and Trial Period	Early ART			Delayed ART			Hazard or Rate Ratio (95% CI)†	Relative Reduction with Early ART vs. Delayed ART
	no. of infections	person-yr of follow-up‡	event rate per 100 person-yr (95% CI)	no. of infections	person-yr of follow-up‡	event rate per 100 person-yr (95% CI)		
All partner infections	19	4324.6	0.44 (0.26–0.69)	59	4184.7	1.41 (1.07–1.82)	0.31 (0.19–0.53)	69
Before interim analysis	4	1751.4	0.23 (0.06–0.58)	42	1731.1	2.43 (1.75–3.28)	0.10 (0.03–0.27)	90
After interim analysis	15	2573.2	0.58 (0.33–0.96)	17	2453.6	0.69 (0.4–1.11)	0.84 (0.39–1.79)	16
Linked partner infections	3	4324.6	0.07 (0.01–0.2)	43	4184.7	1.03 (0.74–1.38)	0.07 (0.02–0.22)	93
Before interim analysis	1	1751.4	0.06 (0–0.32)	36	1731.1	2.08 (1.46–2.88)	0.03 (0.00–0.20)	97
After interim analysis	2	2573.2	0.08 (0.01–0.28)	7	2453.6	0.29 (0.11–0.59)	0.27 (0.03–1.43)	73

* Shown are data with respect to infections that were diagnosed among the partners of index participants during the HPTN 052 trial. Data are shown separately for linked partner infections and all partner infections (linked, unlinked, and linkage status not determined). On May 12, 2011, the investigators released interim study results showing that early antiretroviral therapy (ART) reduced genetically linked HIV-1 transmission by more than 96% and provided health benefits to the index participants. At that time, all index participants were offered ART, regardless of the CD4+ count. Follow-up then continued through May 3, 2015. CI denotes confidence interval.

† Hazard ratios for partner infections during the entire study period and the period before the interim analysis were calculated by means of unstratified univariate Cox regression analysis on an intention-to-treat basis. Rate ratios for partner infections during the period after the interim analysis were calculated according to the person-year analysis.

‡ Follow-up was determined according to the year after randomization.

RELEASE OF INTERIM ANALYSIS

By May 2011, all index participants in the early-ART group and 26% of those in the delayed-ART group had initiated ART. After the release of the interim study results, ART was offered to all index participants in the delayed-ART group regardless of CD4+ count. One year later, 83% of index participants who continued to be followed in the delayed-ART group were receiving ART (Fig. S3 in the Supplementary Appendix). Index participants in the delayed-ART group who chose not to start ART were asked about their decision; most commonly, these participants indicated that they deferred ART because their CD4+ count was too high or because they believed that they were too healthy to begin treatment and risk side effects. By the end of the study, 96% of participants who remained in follow-up in the delayed-ART group had initiated ART (Fig. S3 in the Supplementary Appendix).

TRANSMISSION OF HIV-1 INFECTION TO PARTNERS

We documented HIV-1 infections in 78 partners during the course of the trial, with an incidence of 0.9% (95% confidence interval [CI], 0.7 to 1.1) in the two study groups combined. These infections included 19 in the early-ART group and 59 in the delayed-ART group. The primary end point of the trial was the incidence of genetically linked partner infections, which were identified with the use of phylogenetic and statistical methods.⁹ Of the 78 infections, viral linkage status was determined in 72 (92%), with 6 analytic failures (the viral load was too low for amplification or amplification failed) (Table 1, and Fig. S1 in the Supplementary Appendix).

Of the 72 infections in which viral-linkage status was determined, 26 (36%) — 14 in the early-ART group and 12 in the delayed-ART group — were found to be unlinked, which indicates that the index participant was most likely not the source of the partner’s infection (incidence in the two study groups combined, 0.3%; 95% CI, 0.2 to 0.4). The remaining 46 infections were linked (3 in the early-ART group and 43 in the delayed-ART group). The median CD4+ count of the index participants at the visit before the diagnosis of infection in their partners was 390 cells per cubic millimeter (range, 223 to 748) for linked partner infections and 541 (range, 272 to 1312) for unlinked partner infections.

Eight linked partner HIV-1 infections were

Table 2. Characteristics of Eight Linked Partner Infections Diagnosed after the Index Participant Initiated ART.*

Case	Age at ART Initiation		Index Viral Suppression 6 Mo after ART Initiation†	No. of Days before or after ART Initiation‡				No. of Days between Last Measure of Index Viral Load and Estimated Infection Date	Last Index Viral Load before Estimated Infection Date
	Index Participant	Partner		ART Failure§	Partner's Last Negative HIV-1 Test	Partner's First Positive HIV-1 Test	Estimated Infection Date (95% CI)¶		
	yr							copies/ml	
A	43	52	Yes	NA	-35	35	-5 (-18 to 10)	34	278,398
B	24	24	Yes	NA	-1	84	0 (-32 to 19)	1	87,202
C	50	54	Yes	NA	0	59	5 (-4 to 22)	5	48,316
D	34	34	No	261	-42	49	4	4	>750,000
E	25	29	No	208	1019	1106	1062	43	65,128
F	30	22	Yes	441	1617	1716	1667	50	617
G	46	26	No	362	2095	2228	2162	67	43,486
H	28	19	No	891	860	1419	1140	ND	ND

* HIV-1 infection was diagnosed in eight partners after the infected index participant initiated ART. NA denotes not applicable, and ND not determined.

† “Yes” indicates that the index participant had viral suppression (viral load, <400 copies per milliliter) 6 months after ART initiation.

‡ The number of days between ART initiation (day 0) and other events is shown; negative numbers indicate days before ART initiation; positive numbers indicate days after ART initiation.

§ The initial ART regimen failed in five of the eight index participants. ART failure was defined as a viral load of more than 1000 copies per milliliter on two consecutive visits after receiving ART for more than 24 weeks.

¶ In cases A, B, and C, the index participant had viral suppression at the time that HIV-1 infection was diagnosed in the partner. In those cases, the infection date was estimated with the use of Bayesian evolutionary analysis by sampling trees (BEAST) and other molecular and serologic methods and included 95% confidence intervals.¹⁰ In cases D through H, the infection date was estimated as the midpoint between the partner's last negative test and first positive test for HIV-1.

|| In case H, the partner was lost to follow-up for an extended period. The partner's last negative HIV-1 test was 860 days after the initiation of ART in the index participant, and the partner's first positive HIV-1 test was on day 1419. Four measurements of viral load were obtained for the index participant between day 860 and day 1419 (10,457 copies per milliliter on day 891, 15,944 copies on day 955, <400 copies on day 980, and <400 copies on day 1008).

diagnosed after the index participant had started ART (three in the early-ART group and five in the delayed-ART group). In four cases, the partner was diagnosed with HIV-1 infection less than 90 days after the index participant started ART. In these cases, further analysis suggested that all four of these infections probably occurred before the infection was virally suppressed in the index participant (Table 2). In the other four cases, partner infection occurred after ART failed in the index participant.¹⁰

RISK OF PARTNER HIV-1 INFECTION

In an intention-to-treat analysis to compare the number of linked partner infections in the two study groups (the primary study end point), early ART was associated with a 97% lower risk than was delayed ART as of May 2011 and a 93%

lower risk during the entire study. This analysis also showed an estimated 90% lower risk of all partner infections (regardless of linkage status) as of May 2011 and a 69% lower risk in all partner infections during the entire study in the early-ART group (Table 1).

In the Kaplan–Meier analysis, there was an immediate and sustained reduction in linked partner infections after the initiation of ART in the index participant (Fig. 2). The incidence of HIV-1 infection in the delayed-ART group was 36 per 1731.1 person-years from the beginning of the trial through May 12, 2011, and then fell to 7 per 2453.6 person-years after May 12, 2011, to the end of the trial (Table 1). Detailed information on the incidence of partner infections during each year of study follow-up is provided in Table S2 in the Supplementary Appendix.




Figure 2. Kaplan–Meier Estimates of the Risk of HIV-1 Infection among Partners of Index Participants.

Shown are the cumulative probabilities of all partner infections (Panel A) and genetically linked partner infections (Panel B) during study follow-up. The insets show the same data on an expanded y axis.

ASSOCIATION BETWEEN INFECTION AND STUDY VARIABLES

Univariate and multivariate intention-to-treat analyses were performed to examine the association between the study group and other factors with all partner infections and with linked partner infections (Table 3). In these analyses, the hazard ratios for the association between the study group and partner infection were nearly identical in both univariate and multivariate models. The analysis also showed that an increased CD4+ count among the index participants at baseline was associated with both linked

infections and all infections among partners; in addition, an increased baseline index viral load was associated with linked partner infections. In the delayed-ART group, an increased CD4+ count at baseline was associated with a longer time until the initiation of ART (hazard ratio, 0.90; 95% CI, 0.85 to 0.96; P=0.002), whereas an increased viral load at baseline was associated with a shorter time until the initiation of ART (hazard ratio, 1.31; 95% CI, 1.19 to 1.44; P<0.001). Less frequent condom use (<100%, by self-report by either partner) was associated with an increased risk of both linked infections and all infections among partners.

DISCUSSION

Over the course of our study involving HIV-1 serodiscordant couples, there was a 93% lower risk of genetically linked HIV-1 infection among partners in the early-ART group than in the delayed-ART group in the intention-to-treat analysis. Between May 2011 and May 2015, there were only two cases of linked HIV-1 infection per 2573 person-years of follow-up. After May 2011, couples in the delayed-ART group also derived a benefit from the evolving initiation of ART. However, even during the latter part of the study, the risk of linked HIV-1 infection among partners remained higher in the delayed-ART group than in the early-ART group (Table 1 and Fig. 2, and Table S2 in the Supplementary Appendix).

Over the course of the study, eight genetically linked partner infections were observed after the index participant had initiated ART (three in the early-ART group and five in the delayed-ART group). In all eight cases, the data indicated that the index participant was most likely viremic at the time of HIV-1 transmission, although it was not possible to measure the viral load at the time of the transmission event. The relationship between viremia and HIV transmission that we observed in this study emphasizes the importance of counseling with respect to the potential for HIV-1 transmission before viral suppression is achieved, of close monitoring of the viral load during treatment, and of responding quickly in cases of ART failure.¹¹ Previous studies have reported the transmission of HIV-1 by only one participant in whom the infection was stably suppressed during receipt of ART.^{12,13} However, we did not document any such transmission events in this study.

Table 3. Hazard Ratios for the Association of All Partner Infections and Linked Partner Infections with Study Group, Clinical Factors, and Demographic Factors (Intention-to-Treat Analysis).*

Variable	All Partner Infections		Linked Partner Infections	
	Univariate Analysis	Multivariate Analysis	Univariate Analysis	Multivariate Analysis
	<i>hazard ratio (95% CI)</i>			
Early vs. delayed ART with follow-up through May 2015	0.32 (0.19–0.54)	0.34 (0.20–0.57)	0.07 (0.02–0.22)	0.08 (0.02–0.25)
Baseline CD4+ count per 100 increment	1.19 (1.02–1.38)	1.21 (1.04–1.41)	1.22 (1.02–1.47)	1.25 (1.05–1.48)
Baseline viral load per unit log ₁₀ increment	1.08 (0.82–1.42)	1.18 (0.89–1.56)	1.70 (1.15–2.51)	1.88 (1.24–2.87)
Male sex vs. female sex of index participant	0.85 (0.54–1.35)	0.86 (0.54–1.39)	0.94 (0.52–1.70)	0.86 (0.47–1.59)
Baseline condom use of 100% vs. <100% by either partner	0.34 (0.19–0.64)	0.33 (0.18–0.61)	0.35 (0.16–0.76)	0.34 (0.15–0.75)

* Hazard ratios were calculated by means of both univariate and multivariate Cox regression analysis, stratified according to study site. The results are similar to those calculated by means of unstratified Cox regression analysis (not shown). All the associations were significant ($P < 0.05$) except for baseline viral load in the analysis of all partner infections and male sex versus female sex of the index participant in the analyses of all partner infections and linked partner infections.

After the release of the interim study results, 17% of the index participants in the delayed-ART group initially chose not to start ART, even though they were informed of the personal and public health benefits of such therapy (Fig. S3 in the Supplementary Appendix). This finding probably reflects the relative good health of the participants with HIV-1 infection and the former recommendations of worldwide guidelines that ART was not required for the treatment of infection until there was a decrease in the CD4+ count or a deterioration in health.^{14,15} We hope that the newly emphasized importance of early initiation of ART¹⁶⁻¹⁸ will encourage patients with HIV-1 infection to start such therapy without delay.

Unlinked partner infections (i.e., cases in which the partner was most likely infected by someone other than the enrolled index participant) were observed in the two study groups and represented approximately 30% of partner infections throughout the study; a similar frequency of unlinked infections was reported in another study involving serodiscordant couples.¹⁹ We observed one unlinked partner infection for every 300 person-years of follow-up. The prevention of unlinked HIV-1 infections will require the use of combination prevention strategies that target the broader community.²⁰ Data on the frequency of linked and unlinked partner infections may be helpful for advising HIV-1 serodiscordant

couples^{21,22} and clarifying the assumptions that are used in mathematical modeling and cost-effectiveness exercises.²³

As expected, index participants who had increased viral loads at baseline were significantly more likely to transmit HIV-1 to their sexual partners.²⁴ In contrast, self-reported condom use by either partner was associated with a reduced risk of HIV-1 acquisition. An increased baseline CD4+ count among index participants in the delayed-ART group was associated with a greater probability of linked partner infections, which may reflect a longer delay in the initiation of ART and thus more opportunity for HIV-1 transmission.

Previous observational studies involving participants with HIV-1 infection have shown lower rates of viral transmission both among heterosexual couples^{3,4} and among men who have sex with men²⁵ when the infected person was receiving ART. The final results of the HPTN 052 trial are consistent with those findings and support the importance of viral suppression for HIV-1 prevention. Recent reports have shown that very early initiation of ART can preserve immune function and reduce complications of HIV-1 infection.¹⁶⁻¹⁸ In our study, the early initiation of ART also provided health benefits to the participants receiving treatment.⁸

In 2015, the World Health Organization revised its guidelines to include recommendations

for universal HIV-1 testing and the provision of ART to all persons with HIV-1 infection, regardless of CD4+ count.²¹ Clinical trials are now evaluating the extent to which the provision of early therapy can reduce the population-level incidence of HIV-1 infection.²⁶⁻²⁸ The most effective implementation of ART for HIV-1 prevention on a population level will require intensive HIV-1 testing programs and reliable and sustained programs for immediate and universal access to HIV-1 therapy.²⁹

In conclusion, the final results of the HPTN 052 study show that successful treatment of HIV-1 is a highly effective tool for the prevention of sexual transmission of the virus. These findings support the results of observational studies and

controlled clinical trials showing the personal and public health benefits of the earliest possible initiation of HIV-1 treatment.

The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC.

Presented in part in two abstracts at the 8th International AIDS Society Conference on the Pathogenesis of HIV, Vancouver, BC, Canada, July 19–22, 2015.

Supported by grants (UM1-AI068619 and U01-AI068619, to the HPTN Leadership and Operations Center; UM1-AI068613 and U01-AI068613, to the HPTN Laboratory Center; and UM1-AI068617 and U01-AI068617, to the HPTN Statistical and Data Management Center) from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health and by the NIAID Division of Intramural Research. Study drugs were donated by Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, and Merck.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

APPENDIX

The authors' full names and academic degrees are as follows: Myron S. Cohen, M.D., Ying Q. Chen, Ph.D., Marybeth McCauley, M.P.H., Theresa Gamble, Ph.D., Mina C. Hosseinipour, M.D., Nagalingeswaran Kumarasamy, M.B., B.S., James G. Hakim, M.D., Johnstone Kumwenda, F.R.C.P., Beatriz Grinsztejn, M.D., Jose H.S. Pilotto, M.D., Sheela V. Godbole, M.D., Suwat Chariyalertsak, M.D., Breno R. Santos, M.D., Kenneth H. Mayer, M.D., Irving F. Hoffman, P.A., Susan H. Eshleman, M.D., Ph.D., Estelle Piwowar-Manning, M.T., Leslie Cottle, B.S., Xinyi C. Zhang, Ph.D., Joseph Makhema, M.B., B.Ch., Lisa A. Mills, M.D., Ravindre Panchia, M.B., B.Ch., Sharlaa Faesen, M.B., B.Ch., Joseph Eron, M.D., Joel Gallant, M.D., Diane Havlir, M.D., Susan Swindells, M.B., B.S., Vanessa Elharrar, M.D., David Burns, M.D., Taha E. Taha, M.B., B.S., Karin Nielsen-Saines, M.D., David D. Celentano, Sc.D., Max Essex, D.V.M., Sarah E. Hudelson, B.S., Andrew D. Redd, Ph.D., and Thomas R. Fleming, Ph.D., for the HPTN 052 Study Team

The authors' affiliations are as follows: the Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill (M.S.C., M.C.H., I.F.H., J.E.); the Divisions of Vaccine and Infectious Disease (Y.Q.C., X.C.Z.) and Public Health Science (Y.Q.C.) and the Statistical Center for HIV/AIDS Research and Prevention (L.C.), Fred Hutchinson Cancer Research Center, and the Department of Biostatistics, University of Washington (T.R.F.) — both in Seattle; FHI 360, Washington, DC (M.M.), and Durham, NC (T.G.); Y.R. Gaitonde Center for AIDS Research and Education, Chennai (N.K.), and National AIDS Research Institute, Pune (S.V.G.) — both in India; University of Zimbabwe, Harare (J.G.H.); College of Medicine—Johns Hopkins Project, Blantyre, Malawi (J.K.); Instituto de Pesquisa Clinica Evandro Chagas (B.G.) and Hospital Geral de Nova Iguaçu and Laboratório de AIDS e Imunologia Molecular—IOC/Fiocruz (J.H.S.P.), Rio de Janeiro, and Serviço de Infectologia, Hospital Nossa Senhora da Conceição/GHC, Porto Alegre (B.R.S.) — both in Brazil; Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand (S.C.); Fenway Institute (K.H.M.) and Harvard School of Public Health (M.E.) — both in Boston; the Departments of Pathology (S.H.E., E.P.-M., S.E.H.) and Medicine (A.D.R.), Johns Hopkins University School of Medicine, the Department of Epidemiology, Bloomberg School of Public Health (T.E.T.), and Johns Hopkins Bloomberg School of Public Health (D.D.C.), Baltimore, and the Division of AIDS (V.E., D.B.) and Laboratory of Immunoregulation (A.D.R.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda — both in Maryland; Botswana Harvard AIDS Institute, Gaborone (J.M.); Centers for Disease Control and Prevention (CDC) Division of HIV/AIDS Prevention/KEMRI—CDC Research and Public Health Collaboration HIV Research Branch, Kisumu, Kenya (L.A.M.); Perinatal HIV Research Unit (R.P.) and Clinical HIV Research Unit, Department of Medicine, Faculty of Health Sciences (S.F.), University of the Witwatersrand, Johannesburg; Southwest CARE Center, Santa Fe, NM (J.G.); University of California, San Francisco, San Francisco (D.H.); University of Nebraska Medical Center, Omaha (S.S.); and the Division of Infectious Diseases, David Geffen UCLA School of Medicine, Los Angeles (K.N.-S.).

REFERENCES

- Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. *AIDS* 2013; 27:973-9.
- People living with HIV. UNAIDS. 2014 (<http://aidsinfo.unaids.org/#>).
- Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. *Cochrane Database Syst Rev* 2013;4: CD009153.
- Muessig KE, Cohen MS. Advances in HIV prevention for serodiscordant couples. *Curr HIV/AIDS Rep* 2014;11:434-46.
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011; 365:493-505.
- Cohen MS, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. *Clin Trials* 2012;9:340-7.
- Chen YQ, Masse B, Wang L, et al. Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. *Contemp Clin Trials* 2012;33:1280-6.
- Grinsztejn B, Hosseinipour MC, Ribaldo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis* 2014;14:281-90.
- Eshleman SH, Hudelson SE, Redd AD, et al. Analysis of genetic linkage of HIV

- from couples enrolled in the HIV Prevention Trials Network 052 trial. *J Infect Dis* 2011;204:1918-26.
10. Ping LH, Jabara CB, Rodrigo AG, et al. HIV-1 transmission during early antiretroviral therapy: evaluation of two HIV-1 transmission events in the HPTN 052 prevention study. *PLoS ONE* 2013;8(9):e71557.
 11. Roberts T, Cohn J, Bonner K, Hargreaves S. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. *Clin Infect Dis* 2016;62:1043-8.
 12. Stürmer M, Doerr HW, Berger A, Gute P. Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? *Antivir Ther* 2008;13:729-32.
 13. Vernazza PL, Hirschel B. HIV transmission hunting — the chase for low risk events. *Antivir Ther* 2008;13:641-2.
 14. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? *Lancet* 2013;382:1515-24.
 15. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization, 2013.
 16. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med* 2015;373:808-22.
 17. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. *N Engl J Med* 2013;368:218-30.
 18. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med* 2015;373:795-807.
 19. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. *N Engl J Med* 2010;362:427-39.
 20. El-Sadr WM, Serwadda DM, Sista N, Cohen MS. HIV prevention: great achievements, more challenges ahead. *J Acquir Immune Defic Syndr* 2013;63:Suppl 2:S115-6.
 21. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization, September 2015 (http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf).
 22. Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples: recommendations for a public health approach. Geneva: World Health Organization, 2012.
 23. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. *PLoS Med* 2011;8(11):e1001123.
 24. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. *N Engl J Med* 2000;342:921-9.
 25. Rodger A, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. *JAMA* 2016 July 12 (Epub ahead of print).
 26. Boily MC, Mâsse B, Alsallaq R, et al. HIV treatment as prevention: considerations in the design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. *PLoS Med* 2012;9(7):e1001250.
 27. Cori A, Ayles H, Beyers N, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. *PLoS ONE* 2014;9(1):e84511.
 28. Hayes R, Ayles H, Beyers N, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment — a study protocol for a cluster randomised trial. *Trials* 2014; 15:57.
 29. UNAIDS. 90-90-90: An ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS, 2014.

Copyright © 2016 Massachusetts Medical Society.

RECEIVE IMMEDIATE NOTIFICATION WHEN AN ARTICLE
IS PUBLISHED ONLINE FIRST

To be notified by e-mail when *Journal* articles
are published Online First, sign up at NEJM.org.